$42.83
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow Expands Retina Portfolio With US Launch of Byooviz
Overview
52-week range
$28
$55
56% of range
Avg surprise (last 2)
-1,023%
Avg reaction (last 2)
-2.3%
0% positive
Latest IV / EM
85%
EM ±19.5% · $43 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.63 | $-0.43 | -46.5% | -65.8% | -0.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.03 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $0.24 | — | — | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.38 | $0.02 | -2,000% | — | -4.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.12 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.18 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.13 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.23 | $0.24 | -195.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $17M | — | $18M | $16M | $16M | — | $12M | $13M |
| Gross profit | $27M | — | $54M | $48M | $32M | — | $37M | $36M |
| Operating income | $-22M | — | $15M | $11M | $-11M | — | $1M | $2M |
| Net income | $-28M | — | $1M | $5M | $-18M | — | $-4M | $-6M |
| EPS (diluted) | $-0.74 | — | $0.03 | $0.13 | $-0.50 | — | $-0.12 | $-0.18 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M |
| Inventory | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M |
| Total current assets | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M |
| Total assets | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M |
| Long-term debt | $300M | — | $347M | $251M | $257M | — | $231M | $236M |
| Total liabilities | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M |
| Total equity | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M |